
## Magalie Dosset

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4086448/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Unfolded Protein Response at the Tumor-Immune Interface. Frontiers in Immunology, 2022, 13, 823157.	4.8	11
2	The unfolded protein response links tumor aneuploidy to local immune dysregulation. EMBO Reports, 2021, 22, e52509.	4.5	22
3	Telomerase and CD4 T Cell Immunity in Cancer. Cancers, 2020, 12, 1687.	3.7	20
4	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells, 2020, 9, 1727.	4.1	8
5	Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non–Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 268-279.	3.4	31
6	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. British Journal of Cancer, 2019, 121, 405-416.	6.4	63
7	Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance. Cancer Research, 2019, 79, 5958-5970.	0.9	55
8	Circulating NKp46 <sup>+</sup> Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer. Oncolmmunology, 2019, 8, e1527498.	4.6	28
9	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncolmmunology, 2018, 7, e1433981.	4.6	167
10	Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment. Oncotarget, 2018, 9, 35394-35407.	1.8	6
11	Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells. Nature Communications, 2017, 8, 559.	12.8	67
12	Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice. Oncotarget, 2017, 8, 48959-48971.	1.8	5
13	Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4 <sup>+</sup> Th1 responses against telomerase in cancer patients. Oncolmmunology, 2016, 5, e1137416.	4.6	21
14	Immunogenicity Evaluation of a Rationally Designed Polytope Construct Encoding HLA-A*0201 Restricted Epitopes Derived from Leishmania major Related Proteins in HLA-A2/DR1 Transgenic Mice: Steps toward Polytope Vaccine. PLoS ONE, 2014, 9, e108848.	2.5	28
15	The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nature Immunology, 2014, 15, 758-766.	14.5	187
16	Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 1073-1077.	3.3	20
17	Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. Oncolmmunology, 2013, 2, e23430.	4.6	17
18	Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?. Oncolmmunology, 2012, 1, 1617-1619.	4.6	11

MAGALIE DOSSET

#	Article	IF	CITATIONS
19	Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor. Clinical Cancer Research, 2012, 18, 6284-6295.	7.0	54
20	Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response. Clinical Cancer Research, 2012, 18, 2943-2953.	7.0	97
21	Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood, 2010, 115, 3025-3032.	1.4	30
22	The Angiogenic Growth Factor and Biomarker Midkine Is a Tumor-Shared Antigen. Journal of Immunology, 2010, 185, 418-423.	0.8	30
23	Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice. Vaccine, 2010, 28, 6374-6381.	3.8	10
24	Disulfiram's journey from rubber vulcanization to Tâ $\in \!\! {\mathfrak e}$ ell activation. EMBO Journal, 0, , .	7.8	0